Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

EGF receptor family: Twisting targets for improved cancer therapies.


Jovin,  T.
Emeritus Group Laboratory of Cellular Dynamics, MPI for Biophysical Chemistry, Max Planck Society;

Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Burgess, A. W., Henis, Y. I., Hynes, N. E., Jovin, T., Levitzki, A., Pinkas-Kramarski, R., et al. (2014). EGF receptor family: Twisting targets for improved cancer therapies. Growth Factors, 32(2), 74-81. doi:10.3109/08977194.2014.896355.

Cite as: http://hdl.handle.net/11858/00-001M-0000-0019-126A-9
The epidermal growth factor receptor (EGFR) undergoes a conformational change in response to ligand binding. The ligand-induced changes in cell surface aggregation and mobility have a profound effect on the function of all the family members. Ligand also activates the EGFR intracellular kinase, stimulating proliferation and cell survival. The EGFR family are often activated, overexpressed or mutated in cancer cells and therapeutic drugs (including antibodies) can slow the progress of some cancers. This article provides a brief, annotated summary of the presentations and discussion which occurred at the Epidermal Growth Factor Receptor - Future Directions Conference held in Jerusalem in November 2013.